Cook Medical’s Zilver® PTX® Drug-Eluting Stent Selected As A Top Emerging Health Technology In Canada

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BLOOMINGTON, Ind.--(BUSINESS WIRE)--As announced at the 2014 Canadian Agency for Drugs and Technologies in Health (CADTH) symposium, the Canadian Network for Environmental Scanning in Health (CNESH) has selected Cook Medical’s Zilver® PTX® drug-eluting peripheral stent as a top 10 game-changing health technology for 2014. The CNESH top 10 list is designed to encourage the adoption and use of effective, safe health technologies in Canada.

Zilver PTX is the first self-expanding, drug-eluting stent available to help treat peripheral arterial disease (PAD) in the superficial femoral artery (SFA) in Canada. Approximately 800,000 Canadians have PAD, a growing and pervasive disease. According to CADTH, PAD occurs in four percent of Canadians older than 40, increasing to 20 percent in individuals over the age of 75. Worldwide, recent reports have shown that PAD has reached epidemic levels in developed countries, with 38 million new cases reported in the last 10 years.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC